Monomeric compounds from traditional Chinese medicine: New hopes for drug discovery in pulmonary fibrosis - 03/02/23
Abstract |
Pulmonary fibrosis (PF) is a chronic and irreversible pulmonary disease, and can lead to decreased lung function, respiratory failure and even death. The pathogenesis research and treatment strategy of PF significantly lag behind the medical progress and clinical needs. The treatment of this disease remains a thorny clinical problem, and the effective therapeutic drugs are still limited. Monomeric compounds from traditional Chinese medicine own various biological activities and high safety. They play a broad part in treating diseases and is also a candidate drug for preventing and treating PF. In this paper, we reviewed the mechanism of action and potential value of various anti-PF monomeric compounds from traditional Chinese medicine. These monomeric compounds can attenuate inflammatory response, oxidative stress, epithelial mesenchymal transformation and other processes of lung through many signaling pathways, and inhibit the activation and differentiation of fibroblasts, thus contributing to the treatment of PF. This review can provide new ideas for the development of anti-PF drugs in high efficiency with low toxicity.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abbreviations : AEC, ANG-1–7, AM, AKT, BALF, Bax, Bcl, BLM, CAT, CDK2, CHOP, COL, CTGF, CXCR2, ECM, EGCG, EMT, ER, ERK, FAK, GRP78, GSH-Px, GSK3β, HGF, HIF-α, HMGB1, HYP, HLF, HSP, IFN-γ, IKKβ, IL, iNOS, IκBα, JAK, JNK, LPS, MAPK, MCP, MDA, MMP, MPO, MPP, mTOR, NF-κB, NLRP3, NO, NOX4, NQO1, PDGF-A, PF, PGF, PKCd, PQ, PPAR-γ, PTEN, ROS, SOD, SP-A2, STAT, TGF-β, TIMP, TNF-α, TLR, VEGF, VEGFR, XBP-1, α-SMA
Keywords : Pulmonary fibrosis, Monomeric compounds, Flavonoids, Alkaloid, Terpenoids, Phenols, Saponins, Quinones
Plan
Vol 159
Article 114226- mars 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?